Tag: NeuroPace

NeuroPace initiatives feasibility study of responsive neurostimulation for Lennox-Gastaut syndrome

NeuroPace has announced that the first patient with Lennox-Gastaut syndrome (LGS)—a particularly severe form of childhood-onset epilepsy characterised by cognitive dysfunction and frequent seizures—was...

Why responsive neurostimulation is garnering “wide interest” from the epilepsy field

To date, thalamic responsive neurostimulation (RNS) has shown real potential in the treatment of patients with drug-resistant epilepsy. Mark Richardson (Massachusetts General Hospital, Boston,...

NeuroPace announces first patient implant in NAUTILUS pivotal study

NeuroPace has announced the first patient has been implanted in the NAUTILUS clinical trial, a pivotal study that will evaluate the safety and effectiveness...

NeuroPace announces first treatment in pivotal study evaluating RNS system in...

NeuroPace has announced that the first patient was recently treated in the RESPONSE clinical trial, which is evaluating the safety and effectiveness of the...

NeuroPace gains IDE approval to launch pivotal study of neuromodulation therapy...

NeuroPace has announced that it has received investigational device exemption (IDE) approval from the US Food and Drug Administration (FDA) to initiate the NAUTILUS...
NeuroPace

NeuroPace RNS System receives FDA approval for MRI Labeling, allowing thousands...

NeuroPace has announced that its RNS System has received US Food and Drug Administration (FDA) approval of MRI labeling for the RNS System, expanding...
neuropace NIH

New data demonstrates “unprecedented” efficacy outcomes with the NeuroPace RNS system

NeuroPace has announced that new data from a multicentre, real-world clinical study of the RNS system has demonstrated outcomes never before seen with other...

NIH study to utilise NeuroPace RNS system for research on the...

NeuroPace has announced that the company’s RNS  system, a closed-loop neuromodulation technology approved to treat adults with medically refractory focal onset epilepsy, will be...

NeuroPace present positive data from studies of the RNS System

NeuroPace has presented long-term clinical results demonstrating that the RNS System for refractory epilepsy significantly reduces seizure frequency in patients, with one in three...

NeuroPace announces new Category I CPT code for the RNS system

NeuroPace has announced that the American Medical Association (AMA) has issued a new Category I Current Procedural Terminology (CPT) code for electrocorticography from an implanted...

NeuroPace launches next generation RNS system, the world’s only brain-computer interface...

NeuroPace has announced the launch of its Next Gen RNS System for the treatment of refractory epilepsy. The RNS System is a type of...

NeuroPace closes US$74 million equity funding to accelerate commercialisation of epilepsy...

NeuroPace has closed a US$74 million round of funding led by the KCK Group and OrbiMed Advisors. This funding provides the resources necessary to...